
Quantum BioPharma Advances Multiple Sclerosis Treatment with Investigational New Drug Pathway
Quantum BioPharma has signed an agreement to prepare an Investigational New Drug application for Lucid-21-302, a potential breakthrough therapy targeting multiple sclerosis by preventing demyelination, with plans to submit to the FDA in late 2025.
Read full story






















